Home > Products > Specialty & Industrial Chemicals > Specialty Chemicals > 2-(4-(3-(4-ACETYL-3-HYDROXY-2-PROPYLPHENOXY)PROPOXY)PHENOXY)ACETIC ACID

2-(4-(3-(4-ACETYL-3-HYDROXY-2-PROPYLPHENOXY)PROPOXY)PHENOXY)ACETIC ACID

Name: 2-(4-(3-(4-ACETYL-3-HYDROXY-2-PROPYLPHENOXY)PROPOXY)PHENOXY)ACETIC ACID
Brand: 2A Biotech
SKU: 2A-0114958

CAS Number79558-09-1

Synonyms{4-[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy}acetic acid; l-165,041; L-165041

Molecular FormulaC22H26O7

Molecular Weight402.44

Purity96+%

Density1.2±0.1 g/cm3

Boiling Point600.8±55.0 °C at 760 mmHg

Melting Point127-128ºC(lit.)

EINECS0

MSDSChinese English

Symbol

Signal WordWarning

Cat. No.: 2A-0114958 Purity: 96+%

Change View

Please Login or Create an Account to: See VlP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

Quality Control of [ 79558-09-1 ] Purity: 96+% SDS Specification MoL

Chemical & Physical Properties
CAS Number	79558-09-1
Catalog No.	2A-0114958
Chinese Name	L-165041
Synonyms	{4-[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy}acetic acid; l-165,041; L-165041
Molecular Formula	C22H26O7
Molecular Weight	402.44
Purity	96+
Density	1.2±0.1 g/cm3
Boiling Point	600.8±55.0 °C at 760 mmHg
Melting Point	127-128ºC(lit.)
Application	L-165041 is a cell-penetrating PPARδ agonist with Ki values of 6 nM and approximately 730 nM for PPARδ and PPARγ, respectively, and can induce adipocyte differentiation in NIH-PPARδ cells.
EINECS	0
HTC	2918990090
UN(IATA)	0
PubChem ID	24278477
SMILES	CCCc1c(OCCCOc2ccc(OCC(=O)O)cc2)ccc(C(C)=O)c1O
InChI Key	HBBVCKCCQCQCTJ-UHFFFAOYSA-N
Hazard Symbols	transportation
Bioactivity	L-165041 is a cell permeable PPARδ agonist, with Kis of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively, and induces adipocyte differentiation in NIH-PPARδ cells. Related Catalog Research Areas >> Metabolic Disease Target PPARδ:6 nM (Ki) PPARγ:730 nM (Ki) In Vitro L-165041 is a PPARδ agonist, with Kis of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively[1]. L-165041 (1 or 5 µM) inhibits VEGF-induced endothelial cells (ECs) proliferation and migration. L-165041 negatively affects cell cycle progression in VEGF-activated human umbilical vein ECs (HUVECs). L-165041 (10 µM)inhibits PPARδ-independent, VEGF-induced angiogenesis[2]. PPARδ ligand L-165041 inhibits PDGF-induced rVSMC proliferation and migration. With 1 h of L-165041 pretreatment, PDGF-induced cellular migration is inhibited. L-165041 (10 μM) significantly suppresses S phase transition induced by PDGF[4]. In Vivo L-165041 (5 mg/kg/day, i.p.) significantly lowers the formation of lipid droplets in mice. L-165041 markedly reduces the level of both the hepatic cholesterol and triglycerides in mice. L-165041 increases mRNA expression levels of PPARδ compared to the vehicle group. Lipoprotein lipase (LPL) expression in L-165041-treated mice is significantly higher than that in the vehicle group[3]. Cell Assay Human umbilical vein ECs (HUVECs) are cultured in EGM-2. Subconfluent HUVECs are made quiescent by serum starvation [EBM-2 containing 0.1% fetal bovine serum (FBS)] for 4 h. The cells are pretreated with the PPARδ ligand L-165041 or GW501516 for 6 h followed by VEGF (10 ng/mL) induction[2]. Animal Admin LDLR−/− mice are divided into vehicle (0.1 N NaOH) and L-165041 (5 mg/kg/day) group (9 animals in each group). LDLR−/− mice receive either NaOH or L-165041 via daily intraperitoneal injection (i.p.) for 16 weeks with the Western diet. Body weight is measured once a week and the blood samples for a serum parameter analysis are collected using an eye-bleeding method every 4 weeks. At the end of the experiment, LDLR−/− mice are fasted for 24 h before sacrificed and the liver samples are either fixed in formalin or frozen at −70°C for further analysis. All animals are housed in polycarbonate cages in a room with a 12-h light/12-h dark cycle, and maintained at a constant temperature of 22°C[3]. References [1]. Berger J, et al. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem. 1999 Mar 5;274(10):6718-25. [2]. Park, Jin-Hee., et al. The PPARδ ligand L-165041 inhibits vegf-induced angiogenesis, but the antiangiogenic effect is not related to PPARδ. Journal of Cellular Biochemistry (2012), 113(6), 1947-1954. [3]. Lim, Hyun-Joung., et al. PPARδ ligand L-165041 ameliorates Western diet-induced hepatic lipid accumulation and inflammation in LDLR-/- mice. European Journal of Pharmacology (2009), 622(1-3), 45-51. [4]. Lim, Hyun-Joung., et al. PPARδ agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle. Atherosclerosis (Amsterdam, Netherlands) (2009), 202(2), 446-454. Chemical & Physical Properties Density 1.2±0.1 g/cm3 Boiling Point 600.8±55.0 °C at 760 mmHg Melting Point 127-128ºC(lit.) Molecular Formula C22H26O7 Molecular Weight 402.438 Flash Point 206.5±25.0 °C Exact Mass 402.167847 PSA 102.29000 LogP 4.98 Vapour Pressure 0.0±1.8 mmHg at 25°C Index of Refraction 1.566 InChIKey HBBVCKCCQCQCTJ-UHFFFAOYSA-N SMILES CCCc1c(OCCCOc2ccc(OCC(=O)O)cc2)ccc(C(C)=O)c1O
Use of	L-165041 is a cell permeable PPARδ agonist, with Kis of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively, and induces adipocyte differentiation in NIH-PPARδ cells. Properties Name 2-[4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]acetic acid Synonym More Synonyms L-165041 Biological Activity Description L-165041 is a cell permeable PPARδ agonist, with Kis of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively, and induces adipocyte differentiation in NIH-PPARδ cells. Related Catalog Research Areas >> Metabolic Disease PPARδ:6 nM (Ki) PPARγ:730 nM (Ki) In Vitro L-165041 is a PPARδ agonist, with Kis of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively[1]. L-165041 (1 or 5 µM) inhibits VEGF-induced endothelial cells (ECs) proliferation and migration. L-165041 negatively affects cell cycle progression in VEGF-activated human umbilical vein ECs (HUVECs). L-165041 (10 µM)inhibits PPARδ-independent, VEGF-induced angiogenesis[2]. PPARδ ligand L-165041 inhibits PDGF-induced rVSMC proliferation and migration. With 1 h of L-165041 pretreatment, PDGF-induced cellular migration is inhibited. L-165041 (10 μM) significantly suppresses S phase transition induced by PDGF[4]. References [1]. Berger J, et al. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem. 1999 Mar 5;274(10):6718-25. [2]. Park, Jin-Hee., et al. The PPARδ ligand L-165041 inhibits vegf-induced angiogenesis, but the antiangiogenic effect is not related to PPARδ. Journal of Cellular Biochemistry (2012), 113(6), 1947-1954. [3]. Lim, Hyun-Joung., et al. PPARδ ligand L-165041 ameliorates Western diet-induced hepatic lipid accumulation and inflammation in LDLR-/- mice. European Journal of Pharmacology (2009), 622(1-3), 45-51. [4]. Lim, Hyun-Joung., et al. PPARδ agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle. Atherosclerosis (Amsterdam, Netherlands) (2009), 202(2), 446-454. Chemical & Physical Properties Molecular Formula C22H26O7 Exact Mass 402.167847 PSA 102.29000 Index of Refraction 1.566 InChIKey HBBVCKCCQCQCTJ-UHFFFAOYSA-N
Tax Rebate	13.0%
Supervision	None. MFN tariff: 6.5%. Ordinary tariff: 30.0%
Transport Info	Product name: Purity: 98.0%
MSDS Transport Info	Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available

Related Products in Specialty Chemicals
2-(4-(2-AMINOTHIAZOL-4-YL)PHENOXY)ACETIC ACID	168127-34-2	2A-0114942
2-(4-(2-BROMOPROPANOYL)PHENOXY)ACETIC ACID	33254-93-2	2A-0114945
2-(4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYL)ACETIC ACID	492445-92-8	2A-0114953
2-(4-(2-PHENYLPROPAN-2-YL)PHENOXY)ACETIC ACID	70757-61-8	2A-0114954
2-(4-(2-PHENYLPROPAN-2-YL)PHENOXY)PROPANOIC ACID	70757-66-3	2A-0114956
2-(4-(3-CHLORO-2-HYDROXYPROPOXY)PHENYL)ACETAMIDE	115538-83-5	2A-0114962
2-(4-(3-HYDROXY-3-METHYLBUTYL)PHENOXY)ACETIC ACID	101268-32-0	2A-0114966
2-(4-(4,5-DIHYDROTHIAZOL-2-YL)PHENOXY)ACETONITRILE	175276-95-6	2A-0114973
2-(4-(4-CHLOROBENZYL)-7-FLUORO-5-(METHYLSULFONYL)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID	571170-81-5	2A-0114983
2-(4-(4-FLUOROPHENYL)-2-METHYLTHIAZOL-5-YL)ACETIC ACID	568543-71-5	2A-0114986
Browse all Specialty Chemicals products »

2-(4-(3-(4-ACETYL-3-HYDROXY-2-PROPYLPHENOXY)PROPOXY)PHENOXY)ACETIC ACID

Inquiry Form